| Literature DB >> 29296518 |
Lennart Lenk1, Maren Pein2,3, Olga Will4, Beatriz Gomez1, Fabrice Viol5, Charlotte Hauser6, Jan-Hendrik Egberts6, Jan-Paul Gundlach6, Ole Helm1, Sanjay Tiwari4, Ralf Weiskirchen7, Stefan Rose-John8, Christoph Röcken9, Wolfgang Mikulits10, Patrick Wenzel11, Günter Schneider11, Dieter Saur11, Heiner Schäfer1, Susanne Sebens1.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed when liver metastases already emerged. This study elucidated the impact of hepatic stromal cells on growth behavior of premalignant and malignant pancreatic ductal epithelial cells (PDECs). Liver sections of tumor-bearing KPC mice comprised micrometastases displaying low proliferation located in an unobtrusive hepatic microenvironment whereas macrometastases containing more proliferating cells were surrounded by hepatic myofibroblasts (HMFs). In an age-related syngeneic PDAC mouse model livers with signs of age-related inflammation exhibited significantly more proliferating disseminated tumor cells (DTCs) and micrometastases despite comparable primary tumor growth and DTC numbers. Hepatic stellate cells (HSC), representing a physiologic liver stroma, promoted an IL-8 mediated quiescence-associated phenotype (QAP) of PDECs in coculture. QAP included flattened cell morphology, Ki67-negativity and reduced proliferation, elevated senescence-associated β galactosidase activity and diminished p-Erk/p-p38-ratio. In contrast, proliferation of PDECs was enhanced by VEGF in the presence of HMF. Switching the micromilieu from HSC to HMF or blocking VEGF reversed QAP in PDECs. This study demonstrates how HSCs induce and maintain a reversible QAP in disseminated PDAC cells, while inflammatory HMFs foster QAP reversal and metastatic outgrowth. Overall, the importance of the hepatic microenvironment in induction and reversal of dormancy during PDAC metastasis is emphasized.Entities:
Keywords: dormancy; inflammation; metastases; pancreatic cancer; tumor stroma
Year: 2017 PMID: 29296518 PMCID: PMC5739558 DOI: 10.1080/2162402X.2017.1368603
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110